Recombinant hybrid proteins from pertactin type 1 and 2 of Bordetella pertussis are more immunogenic in mice than the original molecules
Diógenes Quintana‐Vázquez(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Yassel Ramos(Centro de Ingeniería Genética y Biotecnología), Tania Cárdenas(Centro de Ingeniería Genética y Biotecnología), Edelgis Coizeau(Centro de Ingeniería Genética y Biotecnología), Glay Chinea, Guy A. M. Berbers(National Institute for Public Health and the Environment), Anabel Álvarez(Centro de Ingeniería Genética y Biotecnología), Maité Delgado
DOAJ (DOAJ: Directory of Open Access Journals)
March 1, 2014
Cited by 3
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134